IPM.ai

IPM.ai is a healthcare AI and analytics company focused on helping life sciences companies identify, understand, and engage ideal patient populations and their care ecosystems. The business uses real-world data, machine learning, and privacy-safe data infrastructure to support drug development, clinical study planning, product launch, and commercialization, particularly for specialty and rare diseases. IPM.ai does not appear to be a therapeutic drug developer; rather, it provides data-driven products and services to biopharma customers. The company was acquired by W2O Group in January 2021 and now operates as part of Real Chemistry. Its offerings are positioned around patient finding, treatment journey mapping, healthcare provider identification, and commercialization analytics.